Wall Street’s appetite for weight-loss drug stocks over the past four years has powered Eli Lilly & Co. to consistently trade above $1,000 per share. Now, some see the pharma giant’s stock as primed for a split.

The surge in valuation is largely driven by the massive demand for its obesity treatments. As the stock price climbs, market analysts are increasingly discussing a potential split to increase liquidity and accessibility for retail investors.

As the company continues to dominate the metabolic health market, the prospect of a stock split remains a key topic for investors monitoring the pharmaceutical sector's rapid growth.